case_images: PMC8473089_01
case_images: Pathology, PD-L1/CD8 staining images of postoperative tissues. (A) H&E staining of postoperative tissues of the first operation; (B) PD-L1 22C3 IHC staining of the patient's postoperative tissues after recurrence; (C) Positive control of PD-L1 22C3 staining; (D) Negative control of PD-L1 22C3 staining; (E) H&E staining of postoperative tissues after recurrence; (F) CD8 staining of the patient's postoperative tissues after recurrence; (G) Positive control of CD8 staining; (H) Negative control of CD8 staining.
case_images: OTT-14-4891-g0001.jpg
case_images: PMC8473089_01_OTT-14-4891-g0001.jpg
case_images: f0001
case_images: The pathology was poor differentiated pSCC ((Figure 1A), involving the cavernous body of the penis and the cavernous body of the urethra, with nerve invasion and lymphocyte infiltration, and no cancer seen at the cutting edge. Pathology showed that fibrous tissue had cancer infiltration with necrosis (Figure 1E), consistent with recurrence or metastasis of penile squamous cell carcinoma. Tumor Proportion Score (TPS) Interpretation was about 20-30%, while Combined Positive Score (CPS) was about 50-60% (Figure 1B-D). The CD8+ cytotoxic T-lymphocytes (CTLs) was about 30-40% (Figure 1F-H).
case_images: Clinical course and CT image of the case. (A) A scheme shows the time course of the patient in diagnosis and the therapy. (B) Enhanced CT images show the therapeutic response of the patient following a series of treatment.
case_images: OTT-14-4891-g0002.jpg
case_images: PMC8473089_01_OTT-14-4891-g0002.jpg
case_images: f0002
case_images: The tumor showed as an irregular soft tissue shadow, about 10.3 cm by 7.0 cm, with some cystic changes, and no clear boundary with the local muscle (Figure 2B). The patient's treatment plans are presented in a timeline (Figure 2A). The patient reached complete imaging remission (CR) after 4 cycles of combined therapy (Figure 2B). Until Mar 2021, the enhanced CT after 28 cycles (21 months) of sintilimab still presented a sustainable CR (Figure 2B).